Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors
Phase 2
Not yet recruiting
- Conditions
- Gastrointestinal Tumors
- Interventions
- Combination Product: Anti-allergic treatment
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05922358
Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin
Phase 2
Recruiting
- Conditions
- CarcinomaCervix Carcinoma
- Interventions
- Drug: Karelizumab combined with etoposide and cisplatin
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05910177
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05897138
Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer
Phase 1
Not yet recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- Drug: Surufatinib,Serplulimab,Etoposide,Carboplatin
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT05882630
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05839470
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
HRQOL in Locally Advanced Thyroid Carcinoma
Recruiting
- Conditions
- Health Related Quality of LifeTyrosine Kinase InhibitorThyroid Cancer
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05824312
- Locations
- 🇨🇳
Road Fuma No.420, Fuzhou, Fujian, China
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT05799443
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Phase 2
Recruiting
- Conditions
- Ovarian NeoplasmsOvarian Diseases
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT05753826
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fujian, China
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT05751265
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Phase 2
Recruiting
- Conditions
- Immunotherapy Gastrict Cancer
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT05699655
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
© Copyright 2025. All Rights Reserved by MedPath